Antibiotic peptide derived from
View Patent ↗The present invention relates to a peptide derived from the Helicobacter pylori ribosomal protein L1, and the use of this peptide an antibiotic. More specifically, the peptide is derived by making site-specific substitution mutations in a peptide consisting of amino acids 2-20 of the Helicobacter pylori ribosomal protein L1. The resulting peptide has both antibacterial activity and anti-inflammatory activity, but no cytotoxicity.
1. A peptide comprising the amino acid sequence represented by SEQ ID NO:4.
2. The peptide according to claim 1 , wherein the peptide characteristically displays an antibacterial activity against Gram-positive microorganism, Gram-negative microorganism, and antibiotic-resistant strains.
3. The peptide according to claim 2 , wherein the Gram-positive microorganism is Staphylococcus aureus or Bacillus subtilis.
4. The peptide according to claim 2 , wherein the Gram-negative microorganism is Escherichia coli or Pseudomonas aeruginosa.
5. The peptide according to claim 2 , wherein the antibiotic-resistant strain is Gram-positive Staphylococcus aureus or Gram-negative Pseudomonas aeruginosa.
6. A method for treating diseases caused by a pathogenic bacteria comprising the step of administering a pharmaceutically effective dose of the peptide of claim 1 to a subject, wherein the pathogenic bacteria are Staphylococcus aureus, Escherichia coli , and Psuedomonas aeruginosa.